Nutex Health, Inc. (NUTX)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-10-29
$200.15-4.74%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-10-29
Research Workspace
Put NUTX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve EPS of at least $21.52 in FY 2026 and $23.03 in FY 2027: Comparison needs review.
View ThesisRevenue growth is slowing — up about 7% over the past year and decelerating.
View GrowthManagement screens strong on capital allocation, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 54% in its worst 12-month stretch.
View RiskNUTX’s low earnings multiple and cash-backed profits support a hospital-growth thesis, though revenue fell year over year. Q2 FY2026 EPS beat consensus, but reported revenue declined 13.6% year over year. NUTX trades at 9× P/E versus the 23× peer median. The price reflects less growth than our forecast, though the peer comparison is a weak guide. The primary EPS pillar needs review because its comparison is unverified. Our model puts the next-quarter miss probability near 31%. Peer multiples imply a price about 60% above where it trades; the thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. NUTX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering NUTX (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare NUTX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NUTX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put NUTX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Execute growth strategy with new hospital openings
Dual-listing supports growth strategy and visibility.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Improve profitability and operating income
Significant net income increase supports profitability objective.
Advances: Improve profitability and operating income
Upgrade indicates positive outlook on profitability and margins.
